Hing C. Wong - 22 May 2026 Form 4 Insider Report for HCW Biologics Inc. (HCWB)

Reporting relationship: Chief Executive Officer, Director, 10%+ Owner
Issuer ticker: HCWB
Reported as of: 22 May 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 27 May 2026, 19:26:32 UTC
Prior SEC filing: 20 May 2025
Source filing: View source filing
Reporting owner signature: /s/ Nicole Valdivieso, as Attorney-in-Fact for Hing C. Wong

Key filing fact

Hing C. Wong filed Form 4 for HCW Biologics Inc. (HCWB) on 27 May 2026.

Key facts

This page summarizes Hing C. Wong's Form 4 filing for HCW Biologics Inc. (HCWB).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 27 May 2026, 19:26.

Change

Previous filing in this sequence was filed on 20 May 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001866258 Primary reporting owner

Wong Hing C

Relationship: Chief Executive Officer, Director, 10%+ Owner
Address: C/O HCW BIOLOGICS, INC., 2929 N. COMMERCE PARKWAY, MIRAMAR,
Signature: /s/ Nicole Valdivieso, as Attorney-in-Fact for Hing C. Wong
Signature date: 27 May 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

HCWB transaction

Common Stock

Purchase

Transaction value
Shares: +113,879
Change %: +23%
Price: $1.40^*
Shares after: 615,790
Date: 22 May 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

HCWB transaction Derivative

Common Stock Purchase Warrant

Purchase

Transaction value
Shares: +113,879
Change %: +2692%
Price: $0.000000^*
Shares after: 118,110
Date: 22 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 113,879
Exercise price: $1.28
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The reporting person purchased these shares directly from the issuer in a private placement, which purchase is exempt from Section 16(b) in accordance with Rule 16b-3(d) promulgated under the Securities Exchange Act of 1934, as amended.